Longeviti Neuro Solutions, a neurotechnology company focused on advancing innovative solutions that unlock post-operative ultrasound access to the brain, announced the launch of two strategic initiatives: ClearFit AI, a Brain Ultrasound Interface (BUI). Together, these technologies create a persistent acoustic interface to the brain, enabling real-time bedside imaging and supporting future advances in AI-assisted neurosurgical care.

The ClearFit AI platform combines:

ClearFit sonolucent cranial implants

Ultrasound compatibility

Clinical workflow and training support

AI-enhanced imaging

This platform enables the Brain Ultrasound Interface (BUI) — a new category of post-operative neuro access that may reduce reliance on CT and MRI transport, integrate into existing neuro workflows, and position the implant site as a potential foundation for future applications currently under investigation.

As healthcare systems continue to evaluate scalable and cost-conscious technologies, ultrasound-enabled imaging approaches may offer operational advantages in select care environments.

Adjunct imaging technologies may contribute to:

Expanded bedside visualisation capabilities

Reduced operational transport burdens

Increased accessibility to imaging technologies

Imaging workflow efficiency and process optimisation

Any future clinical, operational, or economic benefits will depend on regulatory review, validation activities, adoption patterns, and real-world implementation.

For clinicians, BUI means the ability to assess the brain at the bedside — possibly reducing operational burdens such as scheduling imaging, transporting a post-operative patient, or waiting for results. ClearFit AI™ makes that possible by turning the implant site into a persistent sonolucent interface, with AI-assisted imaging optimisation only available on Clarius Ultrasound units.

For patients, that access may mean fewer trips to the scanner, less radiation exposure, and bedside visualisation that may extend from the ICU into outpatient and recovery settings.

“The mission was always in the name,” said Jesse Christopher, CEO. “Longeviti exists to pursue scalable platform technologies that help create new possibilities for clinicians, researchers, and patients while supporting the broader goal of protecting cognitive function and improving quality of life.”